Skip to main content
Erschienen in: International Ophthalmology 6/2018

05.12.2017 | Original Paper

Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma

verfasst von: Pir Salim Mahar, Nadeem H. Butt, Syed Imtiaz Ali

Erschienen in: International Ophthalmology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the efficacy of locally produced Latanoprost in reducing the intraocular pressure (IOP) in patients with Primary open-angle glaucoma (POAG).

Design

Open-label, non-comparative, observational case study with non-probability purposive sampling.

Methods

A total of 48 patients (94 eyes) of either gender were recruited from glaucoma clinic with the diagnosis of POAG, having IOP of more than 21 mmHg. Patients were commenced on locally produced Latanoprost (Vislat 0.005%). IOP was subsequently measured at 4 weeks and 12 weeks, respectively. The primary end point was reduction in IOP at 12 weeks after the initiation of treatment.

Results

A total of 48 patients (94 eyes) were recruited from glaucoma clinic. The average IOP of our patients at baseline was 28.6 ± 8.1 mmHg, decreasing to 21.3 ± 10.6 mmHg at 4 weeks, indicating a drop of 19.1% (P < 0.001). IOP further decreased to 20.3 ± 8.7 mmHg after 3 months of treatment indicating a decrease of 23.3% (P < 0.001). A decrease in IOP occurred in 51 eyes (71.8%) at 4 weeks after treatment, improving to 54 eyes (76%) at 3-month follow-up. Twenty eyes (28.1%) did not show any change in IOP at 4 weeks. However, after 3-month follow-up only 17 eyes (23.9%) did not reveal any change in IOP.

Conclusion

Our results showed a decrease in IOP of 19.1% after 4 weeks, increasing to 23.3% at 12 weeks in cohort of 37 patients (72 eyes) treated with locally produced Latanoprost (Vislat 0.005%).
Literatur
1.
Zurück zum Zitat Ocklind A (1998) Effect of Latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 67:179–191CrossRef Ocklind A (1998) Effect of Latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 67:179–191CrossRef
2.
Zurück zum Zitat Kim JW, Lindsey JD, Wang N et al (2001) Increased human sclera permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 42:1514–1521PubMed Kim JW, Lindsey JD, Wang N et al (2001) Increased human sclera permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 42:1514–1521PubMed
3.
Zurück zum Zitat Larsson LI (2001) Intraocular pressure over 24 hours after single-dose administration of Latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand 79:567–571CrossRef Larsson LI (2001) Intraocular pressure over 24 hours after single-dose administration of Latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand 79:567–571CrossRef
4.
Zurück zum Zitat Camras CB (1996) Comparison of Latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138–147CrossRef Camras CB (1996) Comparison of Latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138–147CrossRef
5.
Zurück zum Zitat Aml A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743–1752CrossRef Aml A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743–1752CrossRef
6.
Zurück zum Zitat Watson P, Stjernschantz J (1996) A six-month randomized, double-masked study comparing Latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103:126–137CrossRef Watson P, Stjernschantz J (1996) A six-month randomized, double-masked study comparing Latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103:126–137CrossRef
7.
Zurück zum Zitat Hedman K, Watson P, Alm A (2002) The effect of Latanoprost on Intraocular pressure during 2 years of treatment. Survey Ophthalmol 47:65–75CrossRef Hedman K, Watson P, Alm A (2002) The effect of Latanoprost on Intraocular pressure during 2 years of treatment. Survey Ophthalmol 47:65–75CrossRef
8.
Zurück zum Zitat Allauire C, Dietrich A, Allmeir H, Grundmane I, Mazur-Piotrowska G, Kahle G (2012) Latanoprost 0.005%, test formulation is as effective as Xalatan in patients with ocular hypertension and primary open angle glaucoma. Eur J Ophthalmol 22(1):19–27CrossRef Allauire C, Dietrich A, Allmeir H, Grundmane I, Mazur-Piotrowska G, Kahle G (2012) Latanoprost 0.005%, test formulation is as effective as Xalatan in patients with ocular hypertension and primary open angle glaucoma. Eur J Ophthalmol 22(1):19–27CrossRef
9.
Zurück zum Zitat Golan S, Rosenfeld E, Shemesh G, Kurtz S (2015) Original and generic Latanoprost for the treatment of glaucoma and ocular hypertension are really the same? Clin Exp Pharmacol Physiol 42(2):220–224CrossRef Golan S, Rosenfeld E, Shemesh G, Kurtz S (2015) Original and generic Latanoprost for the treatment of glaucoma and ocular hypertension are really the same? Clin Exp Pharmacol Physiol 42(2):220–224CrossRef
10.
Zurück zum Zitat Digiuni M, Manni G, Vetrugno M, Uva M, Milano G, Orzalesi N et al (2013) An evaluation of therapeutic non-inferiority of 0.005% Latanoprost ophthalmic solution and Xalatan in patients with glaucoma or ocular hypertension. J Glaucoma 22(9):707–712CrossRef Digiuni M, Manni G, Vetrugno M, Uva M, Milano G, Orzalesi N et al (2013) An evaluation of therapeutic non-inferiority of 0.005% Latanoprost ophthalmic solution and Xalatan in patients with glaucoma or ocular hypertension. J Glaucoma 22(9):707–712CrossRef
11.
Zurück zum Zitat Hashemi M, Miraftabi A, Nilforoushan N, Ghasemi Falaranjani K, Pakdel F, Soudi R et al (2012) Comparison of the efficacy and tolerability of Xalatan and Xalabiost (Generic Latanoprost) in adults with open angle glaucoma and ocular hypertension. A two-center, randomized crossover trial. Iran J Ophthalmol 24(3):11–18 Hashemi M, Miraftabi A, Nilforoushan N, Ghasemi Falaranjani K, Pakdel F, Soudi R et al (2012) Comparison of the efficacy and tolerability of Xalatan and Xalabiost (Generic Latanoprost) in adults with open angle glaucoma and ocular hypertension. A two-center, randomized crossover trial. Iran J Ophthalmol 24(3):11–18
12.
Zurück zum Zitat Narayanaswamy A, Neog A, Baskaran M, Gewge R, Lingham V, Desai C, Rajadhyaksha V (2007) A randomized crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with gerneric Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 55(2):127–131CrossRef Narayanaswamy A, Neog A, Baskaran M, Gewge R, Lingham V, Desai C, Rajadhyaksha V (2007) A randomized crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with gerneric Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 55(2):127–131CrossRef
13.
Zurück zum Zitat Scherer WJ (2004) A retrospective review of non-responders to Latanoprost. J Ocular Pharmacol Ther 18(3):287–291CrossRef Scherer WJ (2004) A retrospective review of non-responders to Latanoprost. J Ocular Pharmacol Ther 18(3):287–291CrossRef
14.
Zurück zum Zitat Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S (2006) Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jap J Ophthalmol 50(2):153–157CrossRef Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S (2006) Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jap J Ophthalmol 50(2):153–157CrossRef
15.
Zurück zum Zitat Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G et al (2006) An evaluation of the rate of non-responders to Latanoprost therapy. J Glaucoma 15(3):238–243CrossRef Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G et al (2006) An evaluation of the rate of non-responders to Latanoprost therapy. J Glaucoma 15(3):238–243CrossRef
16.
Zurück zum Zitat Stein JD, Shekhawat N, Talwar N, Balkrishnan R (2015) Importance of the introduction of generic Latanoprost on glaucoma medication adherence. Ophthalmol 122(4):738747CrossRef Stein JD, Shekhawat N, Talwar N, Balkrishnan R (2015) Importance of the introduction of generic Latanoprost on glaucoma medication adherence. Ophthalmol 122(4):738747CrossRef
Metadaten
Titel
Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma
verfasst von
Pir Salim Mahar
Nadeem H. Butt
Syed Imtiaz Ali
Publikationsdatum
05.12.2017
Verlag
Springer Netherlands
Erschienen in
International Ophthalmology / Ausgabe 6/2018
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-017-0773-2

Weitere Artikel der Ausgabe 6/2018

International Ophthalmology 6/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.